@article{3a86a4b575284504974e5b6a1b90a57a,
title = "Access to hematopoietic stem cell transplant for patients with sickle cell anemia",
abstract = "Hematopoietic stem cell transplantation (HSCT) is a curative therapy for patients with phenotypically severe sickle cell anemia, and survival rates following matched-sibling HSCT are very high. However, despite cure rates much higher than HSCT for malignant diseases, the field has been slow to adopt this treatment modality for sickle cell anemia. This article explores some of the social forces that may contribute to this dichotomy.",
keywords = "diversity, healthcare disparities, hematopoietic stem cell transplant, hydroxyurea, sickle cell anemia",
author = "Meier, {Emily Riehm} and Theodore Johnson and Kerice Pinkney and Velez, {Maria C.} and Naynesh Kamani and Isaac Odame",
note = "Funding Information: E.R.M. receives unrestricted grant funding from Pfizer and is a consultant for CVS Caremark. N.K. is an employee of AABB. The opinions expressed are those of the author and do not represent the position or views of AABB. M.C.V. is a speaker for NovoNordisk and CSL Behring, principal investigator (PI) for clinical trials with NovoNordisk, Octapharma, My Life Our Future, and Community Counts, and has participated as an advisory board member for Bayer and Octapharma. The authors have no other disclosures or conflicts of interest. Publisher Copyright: {\textcopyright} 2018 Wiley Periodicals, Inc.",
year = "2018",
month = sep,
doi = "10.1002/pbc.27105",
language = "English (US)",
volume = "65",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "9",
}